{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:38:25Z","timestamp":1792791505619,"version":"4.5.0"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03442-2","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:29:23Z","timestamp":1778617763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bridging Therapeutics and Nanotechnology in Dry Eye Disease: A Review of Risk Factors, Drug Delivery Barriers, and Recent and Future Endeavors for Disease Management"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7187-3161","authenticated-orcid":false,"given":"Mayar","family":"Salama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-0513","authenticated-orcid":false,"given":"Islam M.","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6685-8984","authenticated-orcid":false,"given":"Randa","family":"Tag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2964-8639","authenticated-orcid":false,"given":"Ahmed R.","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"3442_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amolm.2025.100090","author":"K Narendra","year":"2025","unstructured":"Narendra K, Singh SK, Deepa CK, Meghana S, Akanth KR, Manjushree M, et al. Exploring new frontiers in dry eye disease: treatments, mechanisms, and diagnostic innovations a comprehensive review. Aspects Mol Med. 2025. https:\/\/doi.org\/10.1016\/j.amolm.2025.100090.","journal-title":"Aspects Mol Med"},{"issue":"12","key":"3442_CR2","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1136\/bjophthalmol-2014-305201","volume":"98","author":"J Vehof","year":"2014","unstructured":"Vehof J, Kozareva D, Hysi PG, Hammond CJ. Prevalence and risk factors of dry eye disease in a British female cohort. Br J Ophthalmol. 2014;98(12):1712\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305201.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3442_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/09286580802228509","volume":"16","author":"E Viso","year":"2009","unstructured":"Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (the Salnes Eye Study). Ophthalmic Epidemiol. 2009;16(1):15\u201321. https:\/\/doi.org\/10.1080\/09286580802228509.","journal-title":"Ophthalmic Epidemiol"},{"issue":"3","key":"3442_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334\u201365. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.003.","journal-title":"Ocul Surf"},{"issue":"37","key":"3442_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022234","volume":"99","author":"X Zhang","year":"2020","unstructured":"Zhang X, Wang L, Zheng Y, Deng L, Huang X. Prevalence of dry eye disease in the elderly: a protocol of systematic review and meta-analysis. Medicine (Baltimore). 2020;99(37):e22234. https:\/\/doi.org\/10.1097\/MD.0000000000022234.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"3442_CR6","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.ophtha.2011.05.029","volume":"118","author":"M Uchino","year":"2011","unstructured":"Uchino M, Nishiwaki Y, Michikawa T, Shirakawa K, Kuwahara E, Yamada M, et al. Prevalence and risk factors of dry eye disease in Japan: Koumi study. Ophthalmology. 2011;118(12):2361\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2011.05.029.","journal-title":"Ophthalmology"},{"issue":"1","key":"3442_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jtos.2018.09.003","volume":"17","author":"JS Kim","year":"2019","unstructured":"Kim JS, Wang MTM, Craig JP. Exploring the Asian ethnic predisposition to dry eye disease in a pediatric population. Ocul Surf. 2019;17(1):70\u20137. https:\/\/doi.org\/10.1016\/j.jtos.2018.09.003.","journal-title":"Ocul Surf"},{"issue":"2","key":"3442_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2026.102627","volume":"49","author":"K Xiao","year":"2025","unstructured":"Xiao K, Li L, Zhang X, Ye Y, Yao Y, Liu Y, et al. Global prevalence of dry eye: a systematic review and meta-analysis. Contact Lens Anterior Eye. 2025;49(2):102627. https:\/\/doi.org\/10.1016\/j.clae.2026.102627.","journal-title":"Contact Lens Anterior Eye"},{"key":"3442_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ajo.2025.09.035","volume":"282","author":"VL Perez","year":"2025","unstructured":"Perez VL, Chen W, Craig JP, Dogru M, Jones L, Stapleton F, et al. TFOS DEWS III: Executive Summary. Am J Ophthalmol. 2025;282:135\u201345. https:\/\/doi.org\/10.1016\/j.ajo.2025.09.035.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"3442_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438\u2013510. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.011.","journal-title":"Ocul Surf"},{"issue":"1","key":"3442_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1444-0938.2011.00634.x","volume":"95","author":"U Stahl","year":"2012","unstructured":"Stahl U, Willcox M, Stapleton F. Osmolality and tear film dynamics. Clin Exp Optom. 2012;95(1):3\u201311. https:\/\/doi.org\/10.1111\/j.1444-0938.2011.00634.x.","journal-title":"Clin Exp Optom"},{"issue":"1","key":"3442_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2021-000709","volume":"6","author":"C Chan","year":"2021","unstructured":"Chan C, Ziai S, Myageri V, Burns JG, Prokopich CL. Economic burden and loss of quality of life from dry eye disease in Canada. BMJ Open Ophthalmol. 2021;6(1):e000709. https:\/\/doi.org\/10.1136\/bmjophth-2021-000709.","journal-title":"BMJ Open Ophthalmol"},{"key":"3442_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jtos.2021.05.006","volume":"21","author":"MK Morthen","year":"2021","unstructured":"Morthen MK, Magno MS, Utheim TP, Snieder H, Hammond CJ, Vehof J. The physical and mental burden of dry eye disease: a large population-based study investigating the relationship with health-related quality of life and its determinants. Ocul Surf. 2021;21:107\u201317. https:\/\/doi.org\/10.1016\/j.jtos.2021.05.006.","journal-title":"Ocul Surf"},{"issue":"4","key":"3442_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","volume":"157","author":"AJ Paulsen","year":"2014","unstructured":"Paulsen AJ, Cruickshanks KJ, Fischer ME, Huang GH, Klein BE, Klein R, et al. Dry eye in the Beaver Dam Offspring Study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol. 2014;157(4):799\u2013806. https:\/\/doi.org\/10.1016\/j.ajo.2013.12.023.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"3442_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539\u201374. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.001.","journal-title":"Ocul Surf"},{"key":"3442_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108115","volume":"197","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder SC, Stern ME. Biological functions of tear film. Exp Eye Res. 2020;197:108115. https:\/\/doi.org\/10.1016\/j.exer.2020.108115.","journal-title":"Exp Eye Res"},{"issue":"3","key":"3442_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","volume":"15","author":"MDP Willcox","year":"2017","unstructured":"Willcox MDP, Argueso P, Georgiev GA, Holopainen JM, Laurie GW, Millar TJ, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15(3):366\u2013403. https:\/\/doi.org\/10.1016\/j.jtos.2017.03.006.","journal-title":"Ocul Surf"},{"issue":"3","key":"3442_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276\u201383. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008.","journal-title":"Ocul Surf"},{"issue":"5","key":"3442_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052434","volume":"23","author":"M Labetoulle","year":"2022","unstructured":"Labetoulle M, Benitez-Del-Castillo JM, Barabino S, Herrero Vanrell R, Daull P, Garrigue JS, et al. Artificial tears: biological role of their ingredients in the management of dry eye disease. Int J Mol Sci. 2022;23(5):2434. https:\/\/doi.org\/10.3390\/ijms23052434.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3442_CR20","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1167\/iovs.10-6997a","volume":"52","author":"KK Nichols","year":"2011","unstructured":"Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922\u20139. https:\/\/doi.org\/10.1167\/iovs.10-6997a.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"3442_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25703","volume":"14","author":"J Singh","year":"2022","unstructured":"Singh J, Priya Y, Bhat V. Prevalence, severity, and treatment outcomes of meibomian gland dysfunction in patients with dry eye symptoms at a tertiary care center in South India. Cureus. 2022;14(6):e25703. https:\/\/doi.org\/10.7759\/cureus.25703.","journal-title":"Cureus"},{"issue":"7","key":"3442_CR22","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1167\/iovs.09-4445","volume":"51","author":"L Tong","year":"2010","unstructured":"Tong L, Chaurasia SS, Mehta JS, Beuerman RW. Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci. 2010;51(7):3449\u201354. https:\/\/doi.org\/10.1167\/iovs.09-4445.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"3442_CR23","doi-asserted-by":"publisher","first-page":"DES102","DOI":"10.1167\/iovs.17-23685","volume":"59","author":"T Kojima","year":"2018","unstructured":"Kojima T. Contact lens-associated dry eye disease: recent advances worldwide and in Japan. Invest Ophthalmol Vis Sci. 2018;59(14):DES102\u20138. https:\/\/doi.org\/10.1167\/iovs.17-23685.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"3442_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ajo.2011.05.025","volume":"152","author":"T Kojima","year":"2011","unstructured":"Kojima T, Ibrahim OM, Wakamatsu T, Tsuyama A, Ogawa J, Matsumoto Y, et al. The impact of contact lens wear and visual display terminal work on ocular surface and tear functions in office workers. Am J Ophthalmol. 2011;152(6):933-40 e2. https:\/\/doi.org\/10.1016\/j.ajo.2011.05.025.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"3442_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/ICO.0b013e31818d3846","volume":"28","author":"EK Akpek","year":"2009","unstructured":"Akpek EK, Klimava A, Thorne JE, Martin D, Lekhanont K, Ostrovsky A. Evaluation of patients with dry eye for presence of underlying Sjogren syndrome. Cornea. 2009;28(5):493\u20137. https:\/\/doi.org\/10.1097\/ICO.0b013e31818d3846.","journal-title":"Cornea"},{"issue":"5","key":"3442_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/ICO.0000000000001865","volume":"38","author":"EK Akpek","year":"2019","unstructured":"Akpek EK, Bunya VY, Saldanha IJ. Sj\u00f6gren\u2019s Syndrome: more than just dry eye. Cornea. 2019;38(5):658\u201361. https:\/\/doi.org\/10.1097\/ICO.0000000000001865.","journal-title":"Cornea"},{"key":"3442_CR27","doi-asserted-by":"publisher","unstructured":"Michaelov E, McKenna C, Ibrahim P, Nayeni M, Dang A, Mather R. Sjogren's Syndrome Associated Dry Eye: Impact on Daily Living and Adherence to Therapy. J Clin Med. 2022;11(10). https:\/\/doi.org\/10.3390\/jcm11102809.","DOI":"10.3390\/jcm11102809"},{"issue":"3","key":"3442_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.sjopt.2013.06.007","volume":"27","author":"A Nassar","year":"2013","unstructured":"Nassar A, Tabbara KF, Aljurf M. Ocular manifestations of graft-versus-host disease. Saudi J Ophthalmol. 2013;27(3):215\u201322. https:\/\/doi.org\/10.1016\/j.sjopt.2013.06.007.","journal-title":"Saudi J Ophthalmol"},{"issue":"5","key":"3442_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1586\/eop.11.56","volume":"6","author":"RM Shtein","year":"2011","unstructured":"Shtein RM. Post-LASIK dry eye. Expert Rev Ophthalmol. 2011;6(5):575\u201382. https:\/\/doi.org\/10.1586\/eop.11.56.","journal-title":"Expert Rev Ophthalmol"},{"key":"3442_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1057685","volume":"10","author":"A Tamimi","year":"2023","unstructured":"Tamimi A, Sheikhzadeh F, Ezabadi SG, Islampanah M, Parhiz P, Fathabadi A, et al. Post-LASIK dry eye disease: a comprehensive review of management and current treatment options. Front Med (Lausanne). 2023;10:1057685. https:\/\/doi.org\/10.3389\/fmed.2023.1057685.","journal-title":"Front Med (Lausanne)"},{"key":"3442_CR31","doi-asserted-by":"publisher","DOI":"10.4103\/2090-0686.174681","author":"MS Mohamed","year":"2015","unstructured":"Mohamed MS, Abu-Steit MH, Shalaby AM, Sherif AM. Evaluation of dry eye syndrome after LASIK and surface ablation: a comparative study. J Egypt Ophthalmol Soc. 2015. https:\/\/doi.org\/10.4103\/2090-0686.174681.","journal-title":"J Egypt Ophthalmol Soc"},{"key":"3442_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030392","author":"E Chlasta-Twardzik","year":"2021","unstructured":"Chlasta-Twardzik E, Gorecka-Niton A, Nowinska A, Wylegala E. The influence of work environment factors on the ocularsurface in a one-year follow-up prospective clinical study. Diagnostics (Basel). 2021. https:\/\/doi.org\/10.3390\/diagnostics11030392.","journal-title":"Diagnostics (Basel)"},{"key":"3442_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009675","author":"R Courtin","year":"2016","unstructured":"Courtin R, Pereira B, Naughton G, Chamoux A, Chiambaretta F, Lanhers C, et al. Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis. BMJ Open. 2016. https:\/\/doi.org\/10.1136\/bmjopen-2015-009675.","journal-title":"BMJ Open"},{"key":"3442_CR34","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.2147\/OPTH.S321591","volume":"15","author":"Z Al-Mohtaseb","year":"2021","unstructured":"Al-Mohtaseb Z, Schachter S, Shen Lee B, Garlich J, Trattler W. The relationship between dry eye disease and digital screen use. Clin Ophthalmol. 2021;15:3811\u201320. https:\/\/doi.org\/10.2147\/OPTH.S321591.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"3442_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/nu13061998","volume":"13","author":"P Fogagnolo","year":"2021","unstructured":"Fogagnolo P, De Cilla S, Alkabes M, Sabella P, Rossetti L. A review of topical and systemic vitamin supplementation in ocular surface diseases. Nutrients. 2021;13(6):1998. https:\/\/doi.org\/10.3390\/nu13061998.","journal-title":"Nutrients"},{"issue":"3","key":"3442_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.sjopt.2014.06.004","volume":"28","author":"AM Al Mahmood","year":"2014","unstructured":"Al Mahmood AM, Al-Swailem SA. Essential fatty acids in the treatment of dry eye syndrome: a myth or reality? Saudi J Ophthalmol. 2014;28(3):195\u20137. https:\/\/doi.org\/10.1016\/j.sjopt.2014.06.004.","journal-title":"Saudi J Ophthalmol"},{"key":"3442_CR37","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.12659\/MSM.891364","volume":"20","author":"A Liu","year":"2014","unstructured":"Liu A, Ji J. Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies. Med Sci Monit. 2014;20:1583\u20139. https:\/\/doi.org\/10.12659\/MSM.891364.","journal-title":"Med Sci Monit"},{"issue":"4","key":"3442_CR38","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s40123-023-00737-6","volume":"12","author":"A Zakrzewska","year":"2023","unstructured":"Zakrzewska A, Wiacek MP, Sluczanowska-Glabowska S, Safranow K, Machalinska A. The effect of oral isotretinoin therapy on Meibomian gland characteristics in patients with Acne vulgaris. Ophthalmol Ther. 2023;12(4):2187\u201397. https:\/\/doi.org\/10.1007\/s40123-023-00737-6.","journal-title":"Ophthalmol Ther"},{"issue":"17","key":"3442_CR39","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.286.17.2114","volume":"286","author":"DA Schaumberg","year":"2001","unstructured":"Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286(17):2114\u20139. https:\/\/doi.org\/10.1001\/jama.286.17.2114.","journal-title":"JAMA"},{"key":"3442_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/vision4020032","author":"BK Foutch","year":"2020","unstructured":"Foutch BK, Sandberg KA, Bennett ES, Naeger LL. Effects of oral antihistamines on tear volume, tear stability, and intraocular pressure. Vision (Basel). 2020. https:\/\/doi.org\/10.3390\/vision4020032.","journal-title":"Vision (Basel)"},{"issue":"1","key":"3442_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.yaoo.2022.03.011","volume":"7","author":"JB Nadelmann","year":"2022","unstructured":"Nadelmann JB, Gupta A, Chung CW, Orlin SE. Stepwise approach to the diagnosis and management of dry eye and ocular surface disease. Adv Ophthalmol Optom. 2022;7(1):325\u201344. https:\/\/doi.org\/10.1016\/j.yaoo.2022.03.011.","journal-title":"Adv Ophthalmol Optom"},{"key":"3442_CR42","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2147\/OPTH.S388289","volume":"17","author":"T Chester","year":"2023","unstructured":"Chester T, Garg SS, Johnston J, Ayers B, Gupta P. How can we best diagnose severity levels of dry eye disease: current perspectives. Clin Ophthalmol. 2023;17:1587\u2013604. https:\/\/doi.org\/10.2147\/OPTH.S388289.","journal-title":"Clin Ophthalmol"},{"key":"3442_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.yaoo.2019.04.002","volume":"4","author":"JA Silbert","year":"2019","unstructured":"Silbert JA, Bitton E, Bhagat K. Advances in diagnosis and management of dry eye disease. Adv Ophthalmol Optom. 2019;4:13\u201338. https:\/\/doi.org\/10.1016\/j.yaoo.2019.04.002.","journal-title":"Adv Ophthalmol Optom"},{"issue":"4","key":"3442_CR44","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.4103\/ijo.IJO_2137_22","volume":"71","author":"SP Srinivas","year":"2023","unstructured":"Srinivas SP, Rao SK. Ocular surface staining: current concepts and techniques. Indian J Ophthalmol. 2023;71(4):1080\u20139. https:\/\/doi.org\/10.4103\/ijo.IJO_2137_22.","journal-title":"Indian J Ophthalmol"},{"issue":"4","key":"3442_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/01.icl.0000253054.10349.2f","volume":"33","author":"E Uchiyama","year":"2007","unstructured":"Uchiyama E, Aronowicz JD, Butovich IA, McCulley JP. Pattern of vital staining and its correlation with aqueous tear deficiency and meibomian gland dropout. Eye Contact Lens. 2007;33(4):177\u20139. https:\/\/doi.org\/10.1097\/01.icl.0000253054.10349.2f.","journal-title":"Eye Contact Lens"},{"key":"3442_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.826530","volume":"8","author":"Y Wu","year":"2021","unstructured":"Wu Y, Wang C, Wang X, Mou Y, Yuan K, Huang X, et al. Advances in Dry Eye Disease Examination Techniques. Front Med (Lausanne). 2021;8:826530. https:\/\/doi.org\/10.3389\/fmed.2021.826530.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"3442_CR47","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ajo.2010.10.032","volume":"151","author":"MA Lemp","year":"2011","unstructured":"Lemp MA, Bron AJ, Baudouin C, Benitez Del Castillo JM, Geffen D, Tauber J, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011;151(5):792-8 e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.10.032.","journal-title":"Am J Ophthalmol"},{"key":"3442_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/704946","volume":"2015","author":"SP Phadatare","year":"2015","unstructured":"Phadatare SP, Momin M, Nighojkar P, Askarkar S, Singh KK. A comprehensive review on dry eye disease: diagnosis, medical management, recent developments, and future challenges. Adv Pharm. 2015;2015:1\u201312. https:\/\/doi.org\/10.1155\/2015\/704946.","journal-title":"Adv Pharm"},{"issue":"3","key":"3442_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.sjopt.2014.06.002","volume":"28","author":"H Lin","year":"2014","unstructured":"Lin H, Yiu SC. Dry eye disease: a review of diagnostic approaches and treatments. Saudi J Ophthalmol. 2014;28(3):173\u201381. https:\/\/doi.org\/10.1016\/j.sjopt.2014.06.002.","journal-title":"Saudi J Ophthalmol"},{"key":"3442_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/gels8020082","author":"MH Akhter","year":"2022","unstructured":"Akhter MH, Ahmad I, Alshahrani MY, Al-Harbi AI, Khalilullah H, Afzal O, et al. Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system. Gels. 2022. https:\/\/doi.org\/10.3390\/gels8020082.","journal-title":"Gels"},{"issue":"11","key":"3442_CR51","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","volume":"58","author":"A Urtti","year":"2006","unstructured":"Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131\u20135. https:\/\/doi.org\/10.1016\/j.addr.2006.07.027.","journal-title":"Adv Drug Deliv Rev"},{"key":"3442_CR52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jconrel.2020.10.025","volume":"328","author":"M Singh","year":"2020","unstructured":"Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release. 2020;328:895\u2013916. https:\/\/doi.org\/10.1016\/j.jconrel.2020.10.025.","journal-title":"J Control Release"},{"issue":"6","key":"3442_CR53","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","volume":"6","author":"V Agrahari","year":"2016","unstructured":"Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6(6):735\u201354. https:\/\/doi.org\/10.1007\/s13346-016-0339-2.","journal-title":"Drug Deliv Transl Res"},{"key":"3442_CR54","first-page":"138","volume":"106","author":"AJ Flach","year":"2008","unstructured":"Flach AJ. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies. Trans Am Ophthalmol Soc. 2008;106:138\u201345.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"2","key":"3442_CR55","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02516-9","volume":"24","author":"S Ahmed","year":"2023","unstructured":"Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS PharmSciTech. 2023;24(2):66. https:\/\/doi.org\/10.1208\/s12249-023-02516-9.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"3442_CR56","first-page":"238","volume":"4","author":"J Barar","year":"2009","unstructured":"Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y. Ocular drug delivery; Impact of in vitro cell culture models. J Ophthalmic Vis Res. 2009;4(4):238\u201352.","journal-title":"J Ophthalmic Vis Res"},{"issue":"1","key":"3442_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.aopr.2024.01.008","volume":"4","author":"Z Lv","year":"2024","unstructured":"Lv Z, Li S, Zeng G, Yao K, Han H. Recent progress of nanomedicine in managing dry eye disease. Adv Ophthalmol Pract Res. 2024;4(1):23\u201331. https:\/\/doi.org\/10.1016\/j.aopr.2024.01.008.","journal-title":"Adv Ophthalmol Pract Res"},{"issue":"4","key":"3442_CR58","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802\u201312. https:\/\/doi.org\/10.1016\/j.jtos.2017.08.003.","journal-title":"Ocul Surf"},{"key":"3442_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering11010039","author":"B Bhujel","year":"2023","unstructured":"Bhujel B, Oh SH, Kim CM, Yoon YJ, Chung HS, Ye EA, et al. Current advances in regenerative strategies for dry eye diseases: a comprehensive review. Bioengineering (Basel). 2023. https:\/\/doi.org\/10.3390\/bioengineering11010039.","journal-title":"Bioengineering (Basel)"},{"key":"3442_CR60","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.2147\/OPTH.S465143","volume":"18","author":"PK Gupta","year":"2024","unstructured":"Gupta PK, Toyos R, Sheppard JD, Toyos M, Mah FS, Bird B, et al. Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies. Clin Ophthalmol. 2024;18:2283\u2013302. https:\/\/doi.org\/10.2147\/OPTH.S465143.","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"3442_CR61","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575\u2013628. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.006.","journal-title":"Ocul Surf"},{"key":"3442_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061289","author":"A Kathuria","year":"2021","unstructured":"Kathuria A, Shamloo K, Jhanji V, Sharma A. Categorization of marketed artificial tear formulations based on their ingredients: a rational approach for their use. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10061289.","journal-title":"J Clin Med"},{"issue":"1","key":"3442_CR63","doi-asserted-by":"publisher","first-page":"P286","DOI":"10.1016\/j.ophtha.2018.10.023","volume":"126","author":"EK Akpek","year":"2019","unstructured":"Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK, et al. Dry Eye Syndrome Preferred Practice Pattern(R). Ophthalmology. 2019;126(1):P286\u2013334. https:\/\/doi.org\/10.1016\/j.ophtha.2018.10.023.","journal-title":"Ophthalmology"},{"key":"3442_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114582","volume":"191","author":"N Nagai","year":"2022","unstructured":"Nagai N, Otake H. Novel drug delivery systems for the management of dry eye. Adv Drug Deliv Rev. 2022;191:114582. https:\/\/doi.org\/10.1016\/j.addr.2022.114582.","journal-title":"Adv Drug Deliv Rev"},{"key":"3442_CR65","doi-asserted-by":"publisher","first-page":"1307682","DOI":"10.3389\/fmed.2024.1307682","volume":"11","author":"L Chu","year":"2024","unstructured":"Chu L, Wang C, Zhou H. Inflammation mechanism and anti-inflammatory therapy of dry eye. Front Med (Lausanne). 2024;11:1307682. https:\/\/doi.org\/10.3389\/fmed.2024.1307682.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3442_CR66","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ejphar.2008.02.044","volume":"586","author":"HY Zhou","year":"2008","unstructured":"Zhou HY, Shin EM, Guo LY, Youn UJ, Bae K, Kang SS, et al. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-\u03baB, JNK and p38 MAPK inactivation. Eur J Pharmacol. 2008;586(1):340\u20139. https:\/\/doi.org\/10.1016\/j.ejphar.2008.02.044.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3442_CR67","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.1.25","volume":"62","author":"W Ouyang","year":"2021","unstructured":"Ouyang W, Wu Y, Lin X, Wang S, Yang Y, Tang L, et al. Role of CD4+ T helper cells in the development of BAC-induced dry eye syndrome in mice. Invest Ophthalmol Vis Sci. 2021;62(1):25. https:\/\/doi.org\/10.1167\/iovs.62.1.25.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3442_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.815075","volume":"8","author":"J Ling","year":"2021","unstructured":"Ling J, Chan BC, Tsang MS, Gao X, Leung PC, Lam CW, et al. Current advances in mechanisms and treatment of dry eye disease: Toward anti-inflammatory and immunomodulatory therapy and Traditional Chinese Medicine. Front Med (Lausanne). 2021;8:815075. https:\/\/doi.org\/10.3389\/fmed.2021.815075.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3442_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/2211-5056.369606","volume":"13","author":"A Nguyen","year":"2023","unstructured":"Nguyen A, Kolluru A, Beglarian T. Dry eye disease: A review of anti-inflammatory therapies. Taiwan J Ophthalmol. 2023;13(1):3\u201312. https:\/\/doi.org\/10.4103\/2211-5056.369606.","journal-title":"Taiwan J Ophthalmol"},{"issue":"8","key":"3442_CR70","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1631\/jzus.2006.B0675","volume":"7","author":"CQ Yang","year":"2006","unstructured":"Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;7(8):675\u20138. https:\/\/doi.org\/10.1631\/jzus.2006.B0675.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"2","key":"3442_CR71","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/09273948.2017.1341988","volume":"27","author":"CA Cutolo","year":"2019","unstructured":"Cutolo CA, Barabino S, Bonzano C, Traverso CE. The use of topical corticosteroids for treatment of dry eye syndrome. Ocul Immunol Inflamm. 2019;27(2):266\u201375. https:\/\/doi.org\/10.1080\/09273948.2017.1341988.","journal-title":"Ocul Immunol Inflamm"},{"key":"3442_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106206","volume":"175","author":"HB Mohamed","year":"2022","unstructured":"Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: A review. Eur J Pharm Sci. 2022;175:106206. https:\/\/doi.org\/10.1016\/j.ejps.2022.106206.","journal-title":"Eur J Pharm Sci"},{"key":"3442_CR73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jtos.2022.08.010","volume":"26","author":"RR Vernhardsdottir","year":"2022","unstructured":"Vernhardsdottir RR, Magno MS, Hynnekleiv L, Lagali N, Dartt DA, Vehof J, et al. Antibiotic treatment for dry eye disease related to Meibomian gland dysfunction and blepharitis - A review. Ocul Surf. 2022;26:211\u201321. https:\/\/doi.org\/10.1016\/j.jtos.2022.08.010.","journal-title":"Ocul Surf"},{"issue":"1","key":"3442_CR74","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/ICL.0000000000000729","volume":"47","author":"R Arita","year":"2021","unstructured":"Arita R, Fukuoka S. Efficacy of Azithromycin eyedrops for individuals with Meibomian gland dysfunction-associated posterior blepharitis. Eye Contact Lens. 2021;47(1):54\u20139. https:\/\/doi.org\/10.1097\/ICL.0000000000000729.","journal-title":"Eye Contact Lens"},{"issue":"5","key":"3442_CR75","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3238\/arztebl.2015.0071","volume":"112","author":"EM Messmer","year":"2015","unstructured":"Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71\u201381. https:\/\/doi.org\/10.3238\/arztebl.2015.0071.","journal-title":"Dtsch Arztebl Int"},{"key":"3442_CR76","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/OPTH.S40798","volume":"8","author":"T Kashima","year":"2014","unstructured":"Kashima T, Itakura H, Akiyama H, Kishi S. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal. Clin Ophthalmol. 2014;8:1003\u201310. https:\/\/doi.org\/10.2147\/OPTH.S40798.","journal-title":"Clin Ophthalmol"},{"key":"3442_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-015-0040-0","volume":"15","author":"K Ueda","year":"2015","unstructured":"Ueda K, Matsumiya W, Otsuka K, Maeda Y, Nagai T, Nakamura M. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol. 2015;15:58. https:\/\/doi.org\/10.1186\/s12886-015-0040-0.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"3442_CR78","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/ojo.OJO_29_2017","volume":"11","author":"S Shrivastava","year":"2018","unstructured":"Shrivastava S, Patkar P, Ramakrishnan R, Kanhere M, Riaz Z. Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes. Oman J Ophthalmol. 2018;11(3):207\u201312. https:\/\/doi.org\/10.4103\/ojo.OJO_29_2017.","journal-title":"Oman J Ophthalmol"},{"issue":"7","key":"3442_CR79","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12325-012-0033-9","volume":"29","author":"M Nakamura","year":"2012","unstructured":"Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther. 2012;29(7):579\u201389. https:\/\/doi.org\/10.1007\/s12325-012-0033-9.","journal-title":"Adv Ther"},{"issue":"6","key":"3442_CR80","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10384-015-0408-y","volume":"59","author":"C Shigeyasu","year":"2015","unstructured":"Shigeyasu C, Yamada M, Akune Y, Tsubota K. Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition. Jpn J Ophthalmol. 2015;59(6):415\u201320. https:\/\/doi.org\/10.1007\/s10384-015-0408-y.","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"3442_CR81","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.4103\/IJO.IJO_2987_22","volume":"71","author":"G Qin","year":"2023","unstructured":"Qin G, Chen J, Li L, Zhang Q, Xu L, Yu S, et al. Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: a meta-analysis and systematic review. Indian J Ophthalmol. 2023;71(4):1316\u201325. https:\/\/doi.org\/10.4103\/IJO.IJO_2987_22.","journal-title":"Indian J Ophthalmol"},{"key":"3442_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12083039","author":"L Demolin","year":"2023","unstructured":"Demolin L, Es-Safi M, Soyfoo MS, Motulsky E. Intense pulsed light therapy in the treatment of dry eye diseases: a systematic review and meta-analysis. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12083039.","journal-title":"J Clin Med"},{"issue":"10","key":"3442_CR83","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s40123-024-01017-7","volume":"13","author":"CP Pac","year":"2024","unstructured":"Pac CP, Munteanu M, Sanchez-Gonzalez JM, Rocha-de-Lossada C, Mercea N, Ferrari F, et al. Long-term impacts of intense pulsed light therapy on ocular surface health and tear film dynamics in patients with dry eye disease: detailed analysis and observations over a 1-year follow-up period. Ophthalmol Ther. 2024;13(10):2715\u201330. https:\/\/doi.org\/10.1007\/s40123-024-01017-7.","journal-title":"Ophthalmol Ther"},{"issue":"4","key":"3442_CR84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/ICL.0000000000000847","volume":"48","author":"D Schanzlin","year":"2022","unstructured":"Schanzlin D, Owen JP, Klein S, Yeh TN, Merchea MM, Bullimore MA. Efficacy of the Systane iLux Thermal Pulsation System for the treatment of meibomian gland dysfunction after 1 week and 1 month: a prospective study. Eye Contact Lens. 2022;48(4):155\u201361. https:\/\/doi.org\/10.1097\/ICL.0000000000000847.","journal-title":"Eye Contact Lens"},{"key":"3442_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2024.102431","volume":"75","author":"E Roucaute","year":"2024","unstructured":"Roucaute E, Huertas-Bello M, Sabater AL. Novel treatments for dry eye syndrome. Curr Opin Pharmacol. 2024;75:102431. https:\/\/doi.org\/10.1016\/j.coph.2024.102431.","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"3442_CR86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009327.pub3","volume":"2","author":"Q Pan","year":"2017","unstructured":"Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;2(2):CD009327. https:\/\/doi.org\/10.1002\/14651858.CD009327.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"3442_CR87","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1007\/s40123-023-00827-5","volume":"12","author":"C Vermeulen","year":"2023","unstructured":"Vermeulen C, van der Burg LLJ, van Geloven N, Eggink CA, Cheng YYY, Nuijts R, et al. Allogeneic serum eye drops: a randomized clinical trial to evaluate the clinical effectiveness of two drop sizes. Ophthalmol Ther. 2023;12(6):3347\u201359. https:\/\/doi.org\/10.1007\/s40123-023-00827-5.","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"3442_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2024.103991","volume":"63","author":"J Janus","year":"2024","unstructured":"Janus J, Chmielewska K, Antoniewicz-Papis J. Allogeneic serum-based eye drops may give better results than autologous drops in Sj\u00f6gren\u2019s syndrome dry eye. Transfus Apher Sci. 2024;63(5):103991. https:\/\/doi.org\/10.1016\/j.transci.2024.103991.","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"3442_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2023.102091","volume":"47","author":"P Kwaku Akowuah","year":"2024","unstructured":"Kwaku Akowuah P, Junior Obinwanne C, Owusu E, Kyeremeh S, Bonsu K, Karikari LAA, et al. Platelet-rich plasma for treating dry eye disease - a systematic review and meta-analysis. Contact Lens Anterior Eye. 2024;47(1):102091. https:\/\/doi.org\/10.1016\/j.clae.2023.102091.","journal-title":"Contact Lens Anterior Eye"},{"issue":"11","key":"3442_CR90","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.15419\/bmrat.v11i11.936","volume":"11","author":"PV Pham","year":"2024","unstructured":"Pham PV, Nguyen ST. Platelet-rich plasma therapy for meibomian gland dysfunction and dry eye: a mini review. Biomed Res Ther. 2024;11(11):6900\u201311. https:\/\/doi.org\/10.15419\/bmrat.v11i11.936.","journal-title":"Biomed Res Ther"},{"issue":"2","key":"3442_CR91","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40123-017-0100-z","volume":"6","author":"JL Alio","year":"2017","unstructured":"Alio JL, Rodriguez AE, Ferreira-Oliveira R, Wrobel-Dudzinska D, Abdelghany AA. Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional, non-randomized study. Ophthalmol Ther. 2017;6(2):285\u201393. https:\/\/doi.org\/10.1007\/s40123-017-0100-z.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"3442_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100938","volume":"6","author":"S Garg","year":"2026","unstructured":"Garg S, Donnenfeld E, Sheppard J, Epitropoulos A, Brady TC. Reproxalap improves ocular redness, tear production, and symptoms in a pivotal dry eye disease chamber trial. Ophthalmol Sci. 2026;6(1):100938. https:\/\/doi.org\/10.1016\/j.xops.2025.100938.","journal-title":"Ophthalmol Sci"},{"key":"3442_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtos.2024.11.008","volume":"35","author":"LE Downie","year":"2025","unstructured":"Downie LE, Craig JP, Stapleton F, Tan J, Jones LW, Ng A, et al. Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: a Phase 2, vehicle-controlled, randomized extension trial. Ocul Surf. 2025;35:15\u201324. https:\/\/doi.org\/10.1016\/j.jtos.2024.11.008.","journal-title":"Ocul Surf"},{"key":"3442_CR94","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","volume":"26","author":"DL Wirta","year":"2022","unstructured":"Wirta DL, Senchyna M, Lewis AE, Evans DG, McLaurin EB, Ousler GW, et al. A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1). Ocul Surf. 2022;26:166\u201373. https:\/\/doi.org\/10.1016\/j.jtos.2022.08.003.","journal-title":"Ocul Surf"},{"key":"3442_CR95","doi-asserted-by":"publisher","unstructured":"Pattar GR, Wirta D, Jerkins G, Paauw J, McLaurin EB, Liu A, et al. Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies. Ophthalmology. 2025. https:\/\/doi.org\/10.1016\/j.ophtha.2025.09.018.","DOI":"10.1016\/j.ophtha.2025.09.018"},{"issue":"9","key":"3442_CR96","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1089\/jop.2023.0056","volume":"39","author":"D Evans","year":"2023","unstructured":"Evans D, Kenyon K, Ousler G, Watson M, Vollmer P, McLaurin EB, et al. Efficacy and safety of the melanocortin pan-agonist PL9643 in a Phase 2 study of patients with dry eye disease. J Ocul Pharmacol Ther. 2023;39(9):600\u201310. https:\/\/doi.org\/10.1089\/jop.2023.0056.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"3442_CR97","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12553-019-00381-w","volume":"10","author":"N Omerovi\u0107","year":"2019","unstructured":"Omerovi\u0107 N, Vrani\u0107 E. Application of nanoparticles in ocular drug delivery systems. Heal Technol. 2019;10(1):61\u201378. https:\/\/doi.org\/10.1007\/s12553-019-00381-w.","journal-title":"Heal Technol"},{"issue":"3-4","key":"3442_CR98","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","volume":"13","author":"SK Sahoo","year":"2008","unstructured":"Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3\u20134):144\u201351. https:\/\/doi.org\/10.1016\/j.drudis.2007.10.021.","journal-title":"Drug Discov Today"},{"key":"3442_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061636","author":"ETM Ahmed","year":"2023","unstructured":"Ahmed ETM, Hassan M, Shamma RN, Makky A, Hassan DH. Controlling the evolution of selective Vancomycin resistance through successful ophthalmic eye-drop preparation of Vancomycin-loaded nanoliposomes using the active-loading method. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15061636.","journal-title":"Pharmaceutics"},{"key":"3442_CR100","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2147\/IJN.S306831","volume":"16","author":"IM Adel","year":"2021","unstructured":"Adel IM, ElMeligy MF, Abdelrahim MEA, Maged A, Abdelkhalek AA, Abdelmoteleb AMM, et al. Design and Characterization of Spray-Dried Proliposomes for the Pulmonary Delivery of Curcumin. Int J Nanomedicine. 2021;16:2667\u201387. https:\/\/doi.org\/10.2147\/IJN.S306831.","journal-title":"Int J Nanomedicine"},{"key":"3442_CR101","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.addr.2021.01.019","volume":"174","author":"SG Antimisiaris","year":"2021","unstructured":"Antimisiaris SG, Marazioti A, Kannavou M, Natsaridis E, Gkartziou F, Kogkos M, et al. Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev. 2021;174:53\u201386. https:\/\/doi.org\/10.1016\/j.addr.2021.01.019.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"3442_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01992-2","volume":"21","author":"S Li","year":"2023","unstructured":"Li S, Chen L, Fu Y. Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. J Nanobiotechnology. 2023;21(1):232. https:\/\/doi.org\/10.1186\/s12951-023-01992-2.","journal-title":"J Nanobiotechnology"},{"issue":"4","key":"3442_CR103","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.4103\/IJO.IJO_2806_22","volume":"71","author":"VP Joshi","year":"2023","unstructured":"Joshi VP, Singh S, Thacker M, Pati F, Vemuganti GK, Basu S, et al. Newer approaches to dry eye therapy: nanotechnology, regenerative medicine, and tissue engineering. Indian J Ophthalmol. 2023;71(4):1292\u2013303. https:\/\/doi.org\/10.4103\/IJO.IJO_2806_22.","journal-title":"Indian J Ophthalmol"},{"key":"3442_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/nano14080669","author":"G Coco","year":"2024","unstructured":"Coco G, Buffon G, Taloni A, Giannaccare G. Recent advances in nanotechnology for the treatment of dry eye disease. Nanomaterials. 2024. https:\/\/doi.org\/10.3390\/nano14080669.","journal-title":"Nanomaterials"},{"key":"3442_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103654","author":"H Qiao","year":"2022","unstructured":"Qiao H, Xu Z, Sun M, Fu S, Zhao F, Wang D, et al. Rebamipide liposome as an effective ocular delivery system for the management of dry eye disease. J Drug Deliv Sci Technol. 2022. https:\/\/doi.org\/10.1016\/j.jddst.2022.103654.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3442_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpolymj.2020.109546","author":"RS Ambekar","year":"2020","unstructured":"Ambekar RS, Choudhary M, Kandasubramanian B. Recent advances in dendrimer-based nanoplatform for cancer treatment: a review. Eur Polym J. 2020. https:\/\/doi.org\/10.1016\/j.eurpolymj.2020.109546.","journal-title":"Eur Polym J"},{"issue":"Pt 2","key":"3442_CR107","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.semcancer.2022.06.003","volume":"86","author":"AD Dey","year":"2022","unstructured":"Dey AD, Bigham A, Esmaeili Y, Ashrafizadeh M, Moghaddam FD, Tan SC, et al. Dendrimers as nanoscale vectors: unlocking the bars of cancer therapy. Semin Cancer Biol. 2022;86(Pt 2):396\u2013419. https:\/\/doi.org\/10.1016\/j.semcancer.2022.06.003.","journal-title":"Semin Cancer Biol"},{"key":"3442_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jics.2022.100516","author":"V Patel","year":"2022","unstructured":"Patel V, Patel P, Patel JV, Patel PM. Dendrimer as a versatile platform for biomedical application: a review. J Indian Chem Soc. 2022. https:\/\/doi.org\/10.1016\/j.jics.2022.100516.","journal-title":"J Indian Chem Soc"},{"issue":"4","key":"3442_CR109","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jtos.2018.05.004","volume":"16","author":"H Lin","year":"2018","unstructured":"Lin H, Liu Y, Kambhampati SP, Hsu CC, Kannan RM, Yiu SC. Subconjunctival dendrimer-drug therapy for the treatment of dry eye in a rabbit model of induced autoimmune dacryoadenitis. Ocul Surf. 2018;16(4):415\u201323. https:\/\/doi.org\/10.1016\/j.jtos.2018.05.004.","journal-title":"Ocul Surf"},{"issue":"46","key":"3442_CR110","doi-asserted-by":"publisher","first-page":"27835","DOI":"10.1039\/d0ra04971a","volume":"10","author":"S Gorantla","year":"2020","unstructured":"Gorantla S, Rapalli VK, Waghule T, Singh PP, Dubey SK, Saha RN, et al. Nanocarriers for ocular drug delivery: current status and translational opportunity. RSC Adv. 2020;10(46):27835\u201355. https:\/\/doi.org\/10.1039\/d0ra04971a.","journal-title":"RSC Adv"},{"issue":"3","key":"3442_CR111","doi-asserted-by":"publisher","first-page":"446","DOI":"10.34172\/apb.2023.056","volume":"13","author":"S Khan","year":"2023","unstructured":"Khan S, Sharma A, Jain V. An overview of nanostructured lipid carriers and its application in drug delivery through different routes. Adv Pharm Bull. 2023;13(3):446\u201360. https:\/\/doi.org\/10.34172\/apb.2023.056.","journal-title":"Adv Pharm Bull"},{"key":"3442_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1421959","volume":"11","author":"MS Baig","year":"2024","unstructured":"Baig MS, Karade SK, Ahmad A, Khan MA, Haque A, Webster TJ, et al. Lipid-based nanoparticles: innovations in ocular drug delivery. Front Mol Biosci. 2024;11:1421959. https:\/\/doi.org\/10.3389\/fmolb.2024.1421959.","journal-title":"Front Mol Biosci"},{"key":"3442_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114721","volume":"194","author":"C Wang","year":"2023","unstructured":"Wang C, Pang Y. Nano-based eye drop: topical and noninvasive therapy for ocular diseases. Adv Drug Deliv Rev. 2023;194:114721. https:\/\/doi.org\/10.1016\/j.addr.2023.114721.","journal-title":"Adv Drug Deliv Rev"},{"key":"3442_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061593","author":"C Viegas","year":"2023","unstructured":"Viegas C, Patricio AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15061593.","journal-title":"Pharmaceutics"},{"key":"3442_CR115","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.actbio.2019.08.035","volume":"99","author":"G Tan","year":"2019","unstructured":"Tan G, Li J, Song Y, Yu Y, Liu D, Pan W. Phenylboronic acid-tethered chondroitin sulfate-based mucoadhesive nanostructured lipid carriers for the treatment of dry eye syndrome. Acta Biomater. 2019;99:350\u201362. https:\/\/doi.org\/10.1016\/j.actbio.2019.08.035.","journal-title":"Acta Biomater"},{"key":"3442_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101581","author":"P Bhardwaj","year":"2020","unstructured":"Bhardwaj P, Tripathi P, Gupta R, Pandey S. Niosomes: a review on niosomal research in the last decade. J Drug Deliv Sci Technol. 2020. https:\/\/doi.org\/10.1016\/j.jddst.2020.101581.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"3442_CR117","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/17425247.2020.1822322","volume":"18","author":"A Verma","year":"2021","unstructured":"Verma A, Tiwari A, Saraf S, Panda PK, Jain A, Jain SK. Emerging potential of niosomes in ocular delivery. Expert Opin Drug Deliv. 2021;18(1):55\u201371. https:\/\/doi.org\/10.1080\/17425247.2020.1822322.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"3442_CR118","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1080\/10408398.2020.1829541","volume":"62","author":"AK Farha","year":"2022","unstructured":"Farha AK, Gan RY, Li HB, Wu DT, Atanasov AG, Gul K, et al. The anticancer potential of the dietary polyphenol rutin: current status, challenges, and perspectives. Crit Rev Food Sci Nutr. 2022;62(3):832\u201359. https:\/\/doi.org\/10.1080\/10408398.2020.1829541.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"5-6","key":"3442_CR119","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.drudis.2012.10.005","volume":"18","author":"L Gan","year":"2013","unstructured":"Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today. 2013;18(5\u20136):290\u20137. https:\/\/doi.org\/10.1016\/j.drudis.2012.10.005.","journal-title":"Drug Discov Today"},{"key":"3442_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.06.022","volume":"567","author":"V Gugleva","year":"2019","unstructured":"Gugleva V, Titeva S, Rangelov S, Momekova D. Design and in vitro evaluation of doxycycline hyclate niosomes as a potential ocular delivery system. Int J Pharm. 2019;567:118431. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.06.022.","journal-title":"Int J Pharm"},{"key":"3442_CR121","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejps.2014.05.020","volume":"62","author":"Q Li","year":"2014","unstructured":"Li Q, Li Z, Zeng W, Ge S, Lu H, Wu C, et al. Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharm Sci. 2014;62:115\u201323. https:\/\/doi.org\/10.1016\/j.ejps.2014.05.020.","journal-title":"Eur J Pharm Sci"},{"key":"3442_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2022.132467","volume":"384","author":"A Cid-Samamed","year":"2022","unstructured":"Cid-Samamed A, Rakmai J, Mejuto JC, Simal-Gandara J, Astray G. Cyclodextrins inclusion complex: preparation methods, analytical techniques and food industry applications. Food Chem. 2022;384:132467. https:\/\/doi.org\/10.1016\/j.foodchem.2022.132467.","journal-title":"Food Chem"},{"issue":"1-2","key":"3442_CR123","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ijpharm.2017.07.044","volume":"529","author":"S Johannsdottir","year":"2017","unstructured":"Johannsdottir S, Kristinsson JK, Fulop Z, Asgrimsdottir G, Stefansson E, Loftsson T. Formulations and toxicologic in vivo studies of aqueous cyclosporin A eye drops with cyclodextrin nanoparticles. Int J Pharm. 2017;529(1\u20132):486\u201390. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.07.044.","journal-title":"Int J Pharm"},{"key":"3442_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2022.120007","volume":"297","author":"P Chaudhari","year":"2022","unstructured":"Chaudhari P, Birangal S, Mavlankar N, Pal A, Mallela LS, Roy S, et al. Oil-free eye drops containing Cyclosporine A\/cyclodextrin\/PVA supramolecular complex as a treatment modality for dry eye disease. Carbohydr Polym. 2022;297:120007. https:\/\/doi.org\/10.1016\/j.carbpol.2022.120007.","journal-title":"Carbohydr Polym"},{"key":"3442_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104936","author":"HMSH Soe","year":"2023","unstructured":"Soe HMSH, Maw PD, Asasutjarit R, Loftsson T, Jansook P. Tacrolimus\/hydroxypropyl-\u03b2-cyclodextrin-loaded nanoemulsions stabilized by Zein-Soluplus\u00ae nanoparticles for retinal diseases. J Drug Deliv Sci Technol. 2023. https:\/\/doi.org\/10.1016\/j.jddst.2023.104936.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"4","key":"3442_CR126","doi-asserted-by":"publisher","first-page":"246","DOI":"10.2174\/1872211314666191224115211","volume":"13","author":"Z Qamar","year":"2019","unstructured":"Qamar Z, Qizilbash FF, Iqubal MK, Ali A, Narang JK, Ali J, et al. Nano-based drug delivery system: recent strategies for the treatment of ocular disease and future perspective. Recent Pat Drug Deliv Formul. 2019;13(4):246\u201354. https:\/\/doi.org\/10.2174\/1872211314666191224115211.","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"3442_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2021.116751","author":"BR Choradiya","year":"2021","unstructured":"Choradiya BR, Patil SB. A comprehensive review on nanoemulsion as an ophthalmic drug delivery system. J Mol Liq. 2021. https:\/\/doi.org\/10.1016\/j.molliq.2021.116751.","journal-title":"J Mol Liq"},{"key":"3442_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105406","author":"MA Attia","year":"2024","unstructured":"Attia MA, Eleraky NE, Abdelazeem K, Safwat MA. Prednisolone loaded-cationic nanoemulsion formulation for uveitis management. J Drug Deliv Sci Technol. 2024. https:\/\/doi.org\/10.1016\/j.jddst.2024.105406.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1-2","key":"3442_CR129","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijpharm.2017.12.005","volume":"537","author":"L Peltonen","year":"2018","unstructured":"Peltonen L, Hirvonen J. Drug nanocrystals - versatile option for formulation of poorly soluble materials. Int J Pharm. 2018;537(1\u20132):73\u201383. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.12.005.","journal-title":"Int J Pharm"},{"key":"3442_CR130","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jconrel.2017.06.003","volume":"260","author":"R Al-Kassas","year":"2017","unstructured":"Al-Kassas R, Bansal M, Shaw J. Nanosizing techniques for improving bioavailability of drugs. J Control Release. 2017;260:202\u201312. https:\/\/doi.org\/10.1016\/j.jconrel.2017.06.003.","journal-title":"J Control Release"},{"issue":"1-2","key":"3442_CR131","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijpharm.2007.03.011","volume":"340","author":"MA Kassem","year":"2007","unstructured":"Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340(1\u20132):126\u201333. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.03.011.","journal-title":"Int J Pharm"},{"key":"3442_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124226","volume":"658","author":"S Fathi-Karkan","year":"2024","unstructured":"Fathi-Karkan S, Amiri Ramsheh N, Arkaban H, Narooie-Noori F, Sargazi S, Mirinejad S, et al. Nanosuspensions in ophthalmology: overcoming challenges and enhancing drug delivery for eye diseases. Int J Pharm. 2024;658:124226. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124226.","journal-title":"Int J Pharm"},{"issue":"1","key":"3442_CR133","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nano.2008.07.003","volume":"5","author":"SM Agnihotri","year":"2009","unstructured":"Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine. 2009;5(1):90\u20135. https:\/\/doi.org\/10.1016\/j.nano.2008.07.003.","journal-title":"Nanomedicine"},{"key":"3442_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2022.212767","volume":"137","author":"Y Wu","year":"2022","unstructured":"Wu Y, Vora LK, Mishra D, Adrianto MF, Gade S, Paredes AJ, et al. Nanosuspension-loaded dissolving bilayer microneedles for hydrophobic drug delivery to the posterior segment of the eye. Biomaterials Advances. 2022;137:212767. https:\/\/doi.org\/10.1016\/j.bioadv.2022.212767.","journal-title":"Biomaterials Advances"},{"key":"3442_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-020-0184-8","volume":"24","author":"S Jacob","year":"2020","unstructured":"Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020;24:3. https:\/\/doi.org\/10.1186\/s40824-020-0184-8.","journal-title":"Biomater Res"},{"key":"3442_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105785","author":"A Chandel","year":"2024","unstructured":"Chandel A, Kandav G. Insights into ocular therapeutics: a comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery. J Drug Deliv Sci Technol. 2024. https:\/\/doi.org\/10.1016\/j.jddst.2024.105785.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"9","key":"3442_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18917","volume":"9","author":"A Hiwrale","year":"2023","unstructured":"Hiwrale A, Bharati S, Pingale P, Rajput A. Nanofibers: a current era in drug delivery system. Heliyon. 2023;9(9):e18917. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18917.","journal-title":"Heliyon"},{"key":"3442_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104847","author":"S Lokhande","year":"2023","unstructured":"Lokhande S, Bhandari Y, Ansari M, Khairnar S, Singh K. Development and evaluation of biodegradable nanofiber insert containing hyaluronic acid for treatment of dry eye syndrome. J Drug Deliv Sci Technol. 2023. https:\/\/doi.org\/10.1016\/j.jddst.2023.104847.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"3442_CR139","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1124\/jpet.119.256933","volume":"370","author":"V Gote","year":"2019","unstructured":"Gote V, Sikder S, Sicotte J, Pal D. Ocular drug delivery: present innovations and future challenges. J Pharmacol Exp Ther. 2019;370(3):602\u201324. https:\/\/doi.org\/10.1124\/jpet.119.256933.","journal-title":"J Pharmacol Exp Ther"},{"key":"3442_CR140","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2015.07.007","volume":"213","author":"TG Coursey","year":"2015","unstructured":"Coursey TG, Henriksson JT, Marcano DC, Shin CS, Isenhart LC, Ahmed F, et al. Dexamethasone nanowafer as an effective therapy for dry eye disease. J Control Release. 2015;213:168\u201374. https:\/\/doi.org\/10.1016\/j.jconrel.2015.07.007.","journal-title":"J Control Release"},{"issue":"7","key":"3442_CR141","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1167\/iovs.16-19074","volume":"57","author":"F Bian","year":"2016","unstructured":"Bian F, Shin CS, Wang C, Pflugfelder SC, Acharya G, De Paiva CS. Dexamethasone drug eluting nanowafers control inflammation in alkali-burned corneas associated with dry eye. Invest Ophthalmol Vis Sci. 2016;57(7):3222\u201330. https:\/\/doi.org\/10.1167\/iovs.16-19074.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3442_CR142","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-01915-8","author":"SF Elhabal","year":"2025","unstructured":"Elhabal SF, Farahat MS, Teaima MH, Elzohairy NA, El-Nabarawi M. Innovate sodium alginate microneedle patches integrated with soft lidocaine invasomes: Advanced strategies for oral ulcerative mucositis treatment via TNF-alpha\/NF-kappaB pathways. Drug Deliv Transl Res. 2025. https:\/\/doi.org\/10.1007\/s13346-025-01915-8.","journal-title":"Drug Deliv Transl Res"},{"key":"3442_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115082","volume":"201","author":"K Glover","year":"2023","unstructured":"Glover K, Mishra D, Gade S, Vora LK, Wu Y, Paredes AJ, et al. Microneedles for advanced ocular drug delivery. Adv Drug Deliv Rev. 2023;201:115082. https:\/\/doi.org\/10.1016\/j.addr.2023.115082.","journal-title":"Adv Drug Deliv Rev"},{"key":"3442_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s10033-025-01188-9","author":"Z Yuan","year":"2025","unstructured":"Yuan Z, Zhang H, Hu W, Yu X, Qin S, Wang C, et al. State-of-the-art review of metallic microneedles: structure, fabrication, and application. Chin J Mech Eng. 2025. https:\/\/doi.org\/10.1186\/s10033-025-01188-9.","journal-title":"Chin J Mech Eng"},{"key":"3442_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17050653","author":"SF Elhabal","year":"2025","unstructured":"Elhabal SF, Faheem AM, Hababeh S, Nelson J, Elzohairy NA, AbdelGhany Morsy SA, et al. Dissolving microneedles containing Lactoferrin nanosuspension for enhancement of antimicrobial and anti-inflammatory effects in the treatment of dry eye disease. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17050653.","journal-title":"Pharmaceutics"},{"issue":"10","key":"3442_CR146","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1021\/ie0507934","volume":"45","author":"C-C Li","year":"2006","unstructured":"Li C-C, Chauhan A. Modeling ophthalmic drug delivery by soaked contact lenses. Ind Eng Chem Res. 2006;45(10):3718\u201334. https:\/\/doi.org\/10.1021\/ie0507934.","journal-title":"Ind Eng Chem Res"},{"key":"3442_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121090","volume":"608","author":"FA Maulvi","year":"2021","unstructured":"Maulvi FA, Desai DT, Shetty KH, Shah DO, Willcox MDP. Advances and challenges in the nanoparticles-laden contact lenses for ocular drug delivery. Int J Pharm. 2021;608:121090. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121090.","journal-title":"Int J Pharm"},{"key":"3442_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics8020014","author":"A ElShaer","year":"2016","unstructured":"ElShaer A, Mustafa S, Kasar M, Thapa S, Ghatora B, Alany RG. Nanoparticle-laden contact lens for controlled ocular delivery of prednisolone: formulation optimization using statistical experimental design. Pharmaceutics. 2016. https:\/\/doi.org\/10.3390\/pharmaceutics8020014.","journal-title":"Pharmaceutics"},{"key":"3442_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120490","volume":"600","author":"AM Al-Mahallawi","year":"2021","unstructured":"Al-Mahallawi AM, Abdelbary AA, El-Zahaby SA. Norfloxacin loaded nano-cubosomes for enhanced management of otitis externa: in vitro and in vivo evaluation. Int J Pharm. 2021;600:120490. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120490.","journal-title":"Int J Pharm"},{"issue":"1-2","key":"3442_CR150","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ijpharm.2018.10.057","volume":"553","author":"NF Younes","year":"2018","unstructured":"Younes NF, Abdel-Halim SA, Elassasy AI. Corneal targeted sertaconazole nitrate loaded cubosomes: preparation, statistical optimization, in vitro characterization, ex vivo permeation and in vivo studies. Int J Pharm. 2018;553(1\u20132):386\u201397. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.10.057.","journal-title":"Int J Pharm"},{"issue":"3","key":"3442_CR151","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-026-03342-5","volume":"27","author":"AM Fahmy","year":"2026","unstructured":"Fahmy AM, Saher O, Attia H, Farag MM, Ahmed S. Harnessing novel tetra-synergistic bilosomes for effective otomycosis management: integrated in-vitro, microbiological and in-vivo studies. AAPS PharmSciTech. 2026;27(3):101. https:\/\/doi.org\/10.1208\/s12249-026-03342-5.","journal-title":"AAPS PharmSciTech"},{"key":"3442_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2023.100213","volume":"6","author":"IM Adel","year":"2023","unstructured":"Adel IM, ElMeligy MF, Amer MS, Elkasabgy NA. Polymeric nanocomposite hydrogel scaffold for jawbone regeneration: the role of rosuvastatin calcium-loaded silica nanoparticles. Int J Pharm X. 2023;6:100213. https:\/\/doi.org\/10.1016\/j.ijpx.2023.100213.","journal-title":"Int J Pharm X"},{"key":"3442_CR153","unstructured":"Commission BP, Office S. British Pharmacopoeia 2011. Stationery Office; 2010."},{"issue":"1","key":"3442_CR154","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1080\/10717544.2022.2103600","volume":"29","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, Amin MM, El-Korany SM, Sayed S. Corneal targeted fenticonazole nitrate-loaded novasomes for the management of ocular candidiasis: preparation, in vitro characterization, ex vivo and in vivo assessments. Drug Deliv. 2022;29(1):2428\u201341. https:\/\/doi.org\/10.1080\/10717544.2022.2103600.","journal-title":"Drug Deliv"},{"key":"3442_CR155","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jconrel.2023.01.018","volume":"354","author":"AL Onugwu","year":"2023","unstructured":"Onugwu AL, Nwagwu CS, Onugwu OS, Echezona AC, Agbo CP, Ihim SA, et al. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases. J Control Release. 2023;354:465\u201388. https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.018.","journal-title":"J Control Release"},{"key":"3442_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.enmm.2023.100900","volume":"20","author":"M Namakka","year":"2023","unstructured":"Namakka M, Rahman MR, Said KAMB, Abdul Mannan M, Patwary AM. A review of nanoparticle synthesis methods, classifications, applications, and characterization. Environ Nanotechnol Monit Manag. 2023;20:100900. https:\/\/doi.org\/10.1016\/j.enmm.2023.100900.","journal-title":"Environ Nanotechnol Monit Manag"},{"issue":"1","key":"3442_CR157","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2162159","volume":"30","author":"HA Elgendy","year":"2023","unstructured":"Elgendy HA, Makky AMA, Elakkad YE, Ismail RM, Younes NF. Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment. Drug Deliv. 2023;30(1):2162159. https:\/\/doi.org\/10.1080\/10717544.2022.2162159.","journal-title":"Drug Deliv"},{"issue":"1","key":"3442_CR158","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2022.2162162","volume":"30","author":"NA Shoman","year":"2023","unstructured":"Shoman NA, Gebreel RM, El-Nabarawi MA, Attia A. Optimization of hyaluronan-enriched cubosomes for bromfenac delivery enhancing corneal permeation: characterization, ex vivo, and in vivo evaluation. Drug Deliv. 2023;30(1):2162162. https:\/\/doi.org\/10.1080\/10717544.2022.2162162.","journal-title":"Drug Deliv"},{"key":"3442_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020221","author":"R Abdelmonem","year":"2021","unstructured":"Abdelmonem R, Elhabal SF, Abdelmalak NS, El-Nabarawi MA, Teaima MH. Formulation and characterization of acetazolamide\/carvedilol niosomal gel for glaucoma treatment: in vitro, and in vivo study. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13020221.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3442_CR160","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1208\/s12249-009-9268-4","volume":"10","author":"HO Ammar","year":"2009","unstructured":"Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10(3):808\u201319. https:\/\/doi.org\/10.1208\/s12249-009-9268-4.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"3442_CR161","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-025-03250-0","volume":"27","author":"MA Tawfik","year":"2025","unstructured":"Tawfik MA, Ahmed S, El-Dahmy RM, Aziz DE. Oleic acid enriched leciplexes as novel mucoadhesive cationic nanocarriers of agomelatine for glaucoma treatment. AAPS PharmSciTech. 2025;27(1):4. https:\/\/doi.org\/10.1208\/s12249-025-03250-0.","journal-title":"AAPS PharmSciTech"},{"issue":"10","key":"3442_CR162","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02857-1","volume":"37","author":"SA Gaballa","year":"2020","unstructured":"Gaballa SA, El Garhy OH, Moharram H, Abdelkader H. Preparation and evaluation of cubosomes\/cubosomal gels for ocular delivery of Beclomethasone Dipropionate for management of uveitis. Pharm Res. 2020;37(10):198. https:\/\/doi.org\/10.1007\/s11095-020-02857-1.","journal-title":"Pharm Res"},{"key":"3442_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102075","author":"M Said","year":"2021","unstructured":"Said M, Aboelwafa AA, Elshafeey AH, Elsayed I. Central composite optimization of ocular mucoadhesive cubosomes for enhanced bioavailability and controlled delivery of voriconazole. J Drug Deliv Sci Technol. 2021. https:\/\/doi.org\/10.1016\/j.jddst.2020.102075.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3442_CR164","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jddst.2018.12.005","volume":"49","author":"N \u00dcst\u00fcnda\u011f Okur","year":"2019","unstructured":"\u00dcst\u00fcnda\u011f Okur N, Yozgatl\u0131 V, Okur ME, Yolta\u015f A, Siafaka PI. Improving therapeutic efficacy of voriconazole against fungal keratitis: thermo-sensitive in situ gels as ophthalmic drug carriers. J Drug Deliv Sci Technol. 2019;49:323\u201333. https:\/\/doi.org\/10.1016\/j.jddst.2018.12.005.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3442_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102112","author":"UD Laddha","year":"2021","unstructured":"Laddha UD, Kshirsagar SJ. Formulation of nanoparticles loaded in situ gel for treatment of dry eye disease: in vitro, ex vivo and in vivo evidences. J Drug Deliv Sci Technol. 2021. https:\/\/doi.org\/10.1016\/j.jddst.2020.102112.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3442_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104267","author":"UD Laddha","year":"2023","unstructured":"Laddha UD, Sandhan PD, Gaikwad SS, Moravkar KK, Kshirsagar SJ. Fabrication of pioglitazone nanoparticles loaded polymeric dispersion for treatment of dry eye disease with in vitro and in vivo investigation. J Drug Deliv Sci Technol. 2023. https:\/\/doi.org\/10.1016\/j.jddst.2023.104267.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3442_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2025.101374","volume":"107","author":"MC Savastano","year":"2025","unstructured":"Savastano MC, Rizzo C, Fossataro C, Bacherini D, Giansanti F, Savastano A, et al. Artificial intelligence in ophthalmology: progress, challenges, and ethical implications. Prog Retin Eye Res. 2025;107:101374. https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101374.","journal-title":"Prog Retin Eye Res"},{"key":"3442_CR168","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70056","author":"PP Nair","year":"2024","unstructured":"Nair PP, Keskar M, Borghare PT, Methwani DA, Nasre Y, Chaudhary M. Artificial intelligence in dry eye disease: a narrative review. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.70056.","journal-title":"Cureus"},{"key":"3442_CR169","doi-asserted-by":"crossref","unstructured":"Emamian MH, Aliyari R, Lanca C, Grzybowski A. Artificial Intelligence in the Diagnosis of Dry Eye. In: Grzybowski A, editor. Artificial intelligence in ophthalmology. Cham: Springer Nature Switzerland; 2025. p. 333\u201348.","DOI":"10.1007\/978-3-031-83756-2_24"},{"key":"3442_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12123167","author":"HK Yang","year":"2022","unstructured":"Yang HK, Che SA, Hyon JY, Han SB. Integration of artificial intelligence into the approach for diagnosis and monitoring of dry eye disease. Diagnostics (Basel). 2022. https:\/\/doi.org\/10.3390\/diagnostics12123167.","journal-title":"Diagnostics (Basel)"},{"issue":"Pt 1","key":"3442_CR171","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/978-3-540-75757-3_96","volume":"10","author":"T Yedidya","year":"2007","unstructured":"Yedidya T, Hartley R, Guillon JP, Kanagasingam Y. Automatic dry eye detection. Medical image computing and computer-assisted intervention\u202f: MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention. 2007;10(Pt 1):792\u20139. https:\/\/doi.org\/10.1007\/978-3-540-75757-3_96.","journal-title":"Medical image computing and computer-assisted intervention : MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention"},{"issue":"12","key":"3442_CR172","doi-asserted-by":"publisher","first-page":"7896","DOI":"10.1167\/iovs.14-15618","volume":"55","author":"YS Chun","year":"2014","unstructured":"Chun YS, Yoon WB, Kim KG, Park IK. Objective assessment of corneal staining using digital image analysis. Invest Ophthalmol Vis Sci. 2014;55(12):7896\u2013903. https:\/\/doi.org\/10.1167\/iovs.14-15618.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"3442_CR173","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1007\/s10792-022-02262-0","volume":"42","author":"Y Yu","year":"2022","unstructured":"Yu Y, Zhou Y, Tian M, Zhou Y, Tan Y, Wu L, et al. Automatic identification of meibomian gland dysfunction with meibography images using deep learning. Int Ophthalmol. 2022;42(11):3275\u201384. https:\/\/doi.org\/10.1007\/s10792-022-02262-0.","journal-title":"Int Ophthalmol"},{"issue":"6","key":"3442_CR174","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1167\/tvst.8.6.37","volume":"8","author":"J Wang","year":"2019","unstructured":"Wang J, Yeh TN, Chakraborty R, Yu SX, Lin MC. A deep learning approach for meibomian gland atrophy evaluation in meibography images. Transl Vis Sci Technol. 2019;8(6):37. https:\/\/doi.org\/10.1167\/tvst.8.6.37.","journal-title":"Transl Vis Sci Technol"},{"key":"3442_CR175","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.774344","author":"Y-Y Zhang","year":"2021","unstructured":"Zhang Y-Y, Zhao H, Lin J-Y, Wu S-N, Liu X-W, Zhang H-D, et al. Artificial intelligence to detect meibomian gland dysfunction from in-vivo laser confocal microscopy. Front Med Lausanne. 2021. https:\/\/doi.org\/10.3389\/fmed.2021.774344.","journal-title":"Front Med Lausanne"},{"issue":"1","key":"3442_CR176","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3509064","volume":"2020","author":"SB Han","year":"2020","unstructured":"Han SB, Liu Y-C, Mohamed-Noriega K, Tong L, Mehta JS. Objective imaging diagnostics for dry eye disease. J Ophthalmol. 2020;2020(1):3509064. https:\/\/doi.org\/10.1155\/2020\/3509064.","journal-title":"J Ophthalmol"},{"issue":"12","key":"3442_CR177","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1109\/JBHI.2020.3026940","volume":"24","author":"L Cruz","year":"2020","unstructured":"Cruz L, Souza JC, Paiva A, Almeida J, Junior GB, Aires KRT, et al. Tear film classification in interferometry eye images using phylogenetic diversity indexes and Ripley\u2019s K Function. IEEE J Biomed Health Inform. 2020;24(12):3491\u20138. https:\/\/doi.org\/10.1109\/JBHI.2020.3026940.","journal-title":"IEEE J Biomed Health Inform"},{"issue":"1","key":"3442_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62636-5","volume":"14","author":"FZ El Barche","year":"2024","unstructured":"El Barche FZ, Benyoussef AA, El Habib Daho M, Lamard A, Quellec G, Cochener B, et al. Automated tear film break-up time measurement for dry eye diagnosis using deep learning. Sci Rep. 2024;14(1):11723. https:\/\/doi.org\/10.1038\/s41598-024-62636-5.","journal-title":"Sci Rep"},{"key":"3442_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14010052","author":"N Yokoi","year":"2023","unstructured":"Yokoi N, Kusada N, Kato H, Furusawa Y, Sotozono C, Georgiev GA. Dry eye subtype classification using videokeratography and deep learning. Diagnostics (Basel). 2023. https:\/\/doi.org\/10.3390\/diagnostics14010052.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"3442_CR180","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0299776","volume":"19","author":"S Kim","year":"2024","unstructured":"Kim S, Park D, Shin Y, Kim MK, Jeon HS, Kim YG, et al. Deep learning-based fully automated grading system for dry eye disease severity. PLoS One. 2024;19(3):e0299776. https:\/\/doi.org\/10.1371\/journal.pone.0299776.","journal-title":"PLoS One"},{"issue":"1","key":"3442_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-96778-x","volume":"15","author":"AD Graham","year":"2025","unstructured":"Graham AD, Wang J, Kothapalli T, Ding JE, Tasho H, Molina A, et al. Artificial intelligence models utilize lifestyle factors to predict dry eye related outcomes. Sci Rep. 2025;15(1):13378. https:\/\/doi.org\/10.1038\/s41598-025-96778-x.","journal-title":"Sci Rep"},{"issue":"4","key":"3442_CR182","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/joco.joco_172_24","volume":"36","author":"M Lu","year":"2024","unstructured":"Lu M, Yang K, Deng X, Fan T, Zhang H, Yang W, et al. Artificial intelligence in clinical diagnosis and treatment of dry eye: Workflows, effectiveness, and evaluation. J Curr Ophthalmol. 2024;36(4):315\u201324. https:\/\/doi.org\/10.4103\/joco.joco_172_24.","journal-title":"J Curr Ophthalmol"},{"key":"3442_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.112255","volume":"211","author":"D Modi","year":"2022","unstructured":"Modi D, Nirmal J, Warsi MH, Bhatia M, Hasan N, Kesharwani P, et al. Formulation and development of tacrolimus-gellan gum nanoformulation for treatment of dry eye disease. Colloids Surf B Biointerfaces. 2022;211:112255. https:\/\/doi.org\/10.1016\/j.colsurfb.2021.112255.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3442_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.105018","author":"M Bhatt","year":"2023","unstructured":"Bhatt M, Shende P. Nano-dimensional in-situ hydrogels of lifitegrast: An advancement in preservation time, sustained release and corneal healing in dry eye syndrome. J Drug Deliv Sci Technol. 2023. https:\/\/doi.org\/10.1016\/j.jddst.2023.105018.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3442_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmt.2022.101411","author":"K Jin","year":"2022","unstructured":"Jin K, Ge Y, Ye Z, Pan X, Yan Y, Mao Z, et al. Anti-oxidative and mucin-compensating dual-functional nano eye drops for synergistic treatment of dry eye disease. Appl Mater Today. 2022. https:\/\/doi.org\/10.1016\/j.apmt.2022.101411.","journal-title":"Appl Mater Today"},{"key":"3442_CR186","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.112351","volume":"212","author":"TZ Wang","year":"2022","unstructured":"Wang TZ, Guan B, Liu XX, Ke LN, Wang JJ, Nan KH. A topical fluorometholone nanoformulation fabricated under aqueous condition for the treatment of dry eye. Colloids Surf B Biointerfaces. 2022;212:112351. https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112351.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3442_CR187","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jiec.2022.09.010","volume":"116","author":"S-N Kim","year":"2022","unstructured":"Kim S-N, Min CH, Kim BH, Lee S, Ji HB, Kim CR, et al. Iontophoretic delivery of dexamethasone-loaded nanoparticles to the anterior segment of the eye. J Ind Eng Chem. 2022;116:199\u2013206. https:\/\/doi.org\/10.1016\/j.jiec.2022.09.010.","journal-title":"J Ind Eng Chem"},{"key":"3442_CR188","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.actbio.2024.07.003","volume":"185","author":"H Zou","year":"2024","unstructured":"Zou H, Hong Y, Xu B, Wang M, Xie H, Lin Q. Multifunctional cerium oxide nanozymes with high ocular surface retention for dry eye disease treatment achieved by restoring redox balance. Acta Biomater. 2024;185:441\u201355. https:\/\/doi.org\/10.1016\/j.actbio.2024.07.003.","journal-title":"Acta Biomater"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03442-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03442-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03442-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:08:23Z","timestamp":1780502903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03442-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":188,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["3442"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03442-2","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"206"}}